申请人:Bristol-Myers Company
公开号:US04701459A1
公开(公告)日:1987-10-20
Novel series of 2,3-dihydro-2-oxo-1H-imidazo[4,5-b]quinolinyl amine derivatives of Formula ##STR1## wherein R.sub.1 is hydrogen, lower alkyl; R.sub.2 is hydrogen, lower alkyl, lower alkoxy, halogen; R.sub.3 is hydrogen, lower alkyl; R.sub.4 is hydrogen, lower alkyl, alkanoyl, phenylalkanoyl wherein phenyl is optionally substituted with halogen, lower alkyl, lower alkoxy; R.sub.3 and R.sub.4 are joined together to form morpholinyl, piperidinyl or pyrrolidinyl optionally substituted with --CO.sub.2 R.sub.5 or ##STR2## wherein R.sub.5 is hydrogen or lower alkyl, and R.sub.6 is hydrogen, lower alkyl, cycloalkyl; 4-R.sub.7 -piperazinyl wherein R.sub.7 is --CO.sub.2 R.sub.8 wherein R.sub.8 is lower alkyl, phenyl optionally substituted with up to 2 halogen, lower alkyl or lower alkoxy; phenylalkanoyl of 7 to 10 carbon wherein phenyl is unsubstituted or independently substituted with up to 2 halogen, lower alkyl, lower alkoxy. The compounds are cyclic AMP phosphodiesterase inhibitors and are particularly useful as inhibitors of blood platelet aggregation and/or as cardiotonic agents.
2,3-二氢-2-氧基-1H-咪唑并[4,5-b]喹啉基胺衍生物的小说系列,化学式如下:其中R.sub.1是氢,较低的烷基;R.sub.2是氢,较低的烷基,较低的烷氧基,卤素;R.sub.3是氢,较低的烷基;R.sub.4是氢,较低的烷基,烷酰基,苯基烷酰基,其中苯基可以选择性地用卤素,较低的烷基,较低的烷氧基取代;R.sub.3和R.sub.4结合在一起形成吗啡啉基,哌啶基或吡咯啉基,可以选择性地用--CO.sub.2 R.sub.5或##STR2##取代,其中R.sub.5是氢或较低的烷基,R.sub.6是氢,较低的烷基,环烷基;4-R.sub.7-哌嗪基,其中R.sub.7是--CO.sub.2 R.sub.8,其中R.sub.8是较低的烷基,苯基,可以选择性地用最多2个卤素,较低的烷基或较低的烷氧基取代;含有7至10碳的苯基烷酰基,其中苯基未取代或独立地取代最多2个卤素,较低的烷基,较低的烷氧基。这些化合物是环磷酸腺苷磷酸二酯酶抑制剂,特别适用于抑制血小板聚集和/或作为心力补充剂。